SCHEMBL4934571

SCHEMBL4934571

O=C(Nc1csnc1C(=O)O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
MAPT P10636 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
PKM P14618 2/20 0.50
GRIK1 P39086 1/20 0.50
KDM4D Q6B0I6 1/20 0.48
KDM4C Q9H3R0 1/20 0.48
MDM4 O15151 1/20 0.47
TP53 P04637 1/20 0.47
HDAC3 O15379 1/20 0.47
MAPK1 P28482 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
POLB P06746 1/20 0.47
HPGD P15428 1/20 0.47
PDPK1 O15530 1/20 0.46
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
CYP1A2 P05177 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4893822 0.81 KMT2A (0.50) MEN1KMT2ATDP1NPC1RAB9A
SCHEMBL3616663 0.76 SMN1; SMN2 (0.50) MEN1KMT2AMAPTTP53MAPK1
SCHEMBL4565974 0.75 MEN1 (0.64) MEN1KMT2AMAPTTDP1PKM
SCHEMBL1110180 0.72 MDM4 (0.73) MEN1KMT2AMAPTTDP1PKM
SCHEMBL27874235 0.72 KDR (0.63) MEN1KMT2AMAPTTDP1PKM
SCHEMBL19509669 0.71 HDAC3 (0.66) MEN1KMT2AMAPTTDP1PKM
SCHEMBL2801723 0.71 KMT2A (0.54) MEN1KMT2AMAPTTDP1PKM
SCHEMBL27603002 0.70 HDAC2 (0.64) MEN1KMT2AMAPTTDP1PKM
SCHEMBL4565707 0.69 MEN1 (0.55) MEN1KMT2AMAPTTDP1PKM
SCHEMBL4932652 0.69 KDM4E (0.51) MEN1KMT2AMAPTMDM4TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080167309-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS, LTD. (UK) 2008-07-10 US claimed
EP-1781647-A2 THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS Astex Therapeutics Limited (GB) 2007-05-09 EP claimed
WO-2006008545-A2 THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-01-26 WO claimed
US-20080167309-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS, LTD. (UK) 2008-07-10 US disclosed
EP-1781647-A2 THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS Astex Therapeutics Limited (GB) 2007-05-09 EP disclosed
WO-2006008545-A2 THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167309-A1 Pharmaceutical Compounds CCNO, CDK2, CDK1 MEN1 1071/4885KMT2A 775/4885MAPT 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.